Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Links shared publicly online about this topic.

1,112
total visits

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

View full resource at news-medical.net

Tags: Cancer, Chemotherapy, Colorectal Cancer Medication, Ovarian Cancer, Women's Health, Avastin, Genentech, Oncology